JLE

Hépato-Gastro & Oncologie Digestive

MENU

Traitement de l’encéphalopathie hépatique récidivante par transplantation fécale à donneur sélectionné : une étude pilote Volume 25, numéro 5, Mai 2018

  • [1] Woodhouse C.A., Patel V.C., Singanayagam A., Shawcross D.L. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47:192-202.
  • [2] Fukui H. Gut microbiome-based therapeutics in liver cirrhosis: basic considerations for the next step. J Clin Translational Hepatology. 2017;5:249-260.
  • [3] Bajaj J.S., Hylemon P.B., Ridlon J.M. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303:G675-G685.
  • [4] Bajaj J.S., Heuman D.M., Sterling R.K. Validation of EncephalApp, smartphone-based Stroop test, for the diagnosis of covert hepatic encephalopathy. Clin Gastroenterol Hepatol. 2015;13:1828-1835.
  • [5] Moayyedi P., Surette M.G., Kim P.T. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102-109.